Ventricular assist devices (VADs) have become an important therapy for advanced heart failure, however, the prognosis of those who receive a biventricular assist device (BiVAD) is still poor. We enrolled 70 patients who underwent paracorporeal VAD (Nipro-VAD ) implantation between 2004 and 2015 and studied the preoperative risk factors, including hemodynamic parameters for RVAD requirement. Furthermore, 2-year survival was compared between the BiVAD group and LVAD only group. Fourteen patients (20%) required RVAD. The BiVAD group had a significantly smaller left ventricular diastolic/systolic dimension, lower mean pulmonary artery wedge pressure (PAWP), lower cardiac index (CI), higher pulmonary vascular resistance (PVR), higher mean right atrial pressure (RAP), lower pulmonary artery pulsatility index (PAPi), lower right ventricular stroke work index (RVSWI), and higher mean RAP/mean PAWP ratio preoperatively. After multivariate analysis, only PVR > 4.5 Wood units: WU (P = 0.013, odds ratio: OR 7.9) and mean RAP/mean PAWP > 0.8 (P < 0.001, OR 14.4) were significant predictors for RVAD requirement. From these odds ratios, we assigned 1 point to PVR > 4.5 WU and 2 points to mean RAP/mean PAWP > 0.8. This simple scoring method adequately stratified the incidence of RVAD implantation (score 0: 4.4%, score 1: 28.6%, score 2: 41.7%, score 3: 83.3%). The cumulative survival rate at 2-year after VAD implantation was significantly worse among patients who required RVAD support compared to the LVAD only group (28.5% versus 74.4%, P = 0.009). RVAD requirement is associated with poor long-term survival, and this simple scoring system using PVR and mean RAP/mean PAWP may be useful for predicting RVAD requirement in such patients. (Int Heart J 2018; 59: 983-990) 
T he number of heart failure (HF) patients has been increasing worldwide and severe HF patients still have poor survival. 1) Ventricular assist devices (VADs) have become a crucial therapy for treating such severe HF patients who are refractory to optimal medical therapy.
2) However, those who require a right ventricular assist device (RVAD) in addition to a left ventricular assist device (LVAD) have still been reported to have a poor prognosis. From the 7th INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) annual report, even among continuous flow LVAD patients, the 1-year survival rate of patients with a biventricular assist device (BiVAD) is only 50% in comparison to 80% in the LVAD only patients.
3) Furthermore, the survival rate is much worse in cases of paracorporeal BiVAD including RVAD using a centrifugal pump. 4) In such a cohort of patients, the incidences of complications like bleeding, thrombosis, and infection become high and survival rate worsens. Several risk factors have been reported to be useful for predicting RVAD requirement, 5, 6) however, controversies still remain. The aim of the present study was to identify the preoperative predictors for RVAD requirement among patients who received paracorporeal LVAD.
Methods

Study patients:
We experienced consecutive 93 cases who were implanted with a pulsatile paracorporeal VAD (Nipro-VAD , Nipro Corporation, Japan) between 2004 and 2015. Of these 93 patients, 23 were excluded due to the lack of adequate perioperative clinical and hemodynamic data. Thus, 70 patients were enrolled and analyzed retrospectively.
Implantable VADs were approved in April 2011 by the Japanese national health insurance program as a bridge to transplantation (BTT). In the present study, 38 patients were implanted with a paracorporeal VAD before April 2011. The other 32 patients received a paracorporeal VAD after April 2011 due to cardiogenic shock or insufficient time for examination for HTx listing at that time. All patients received a Nipro-VAD LVAD and written informed consent was obtained from all the patients beforehand. Measurements: Demographic, laboratory, and echocardiographic variables within 24 hours before VAD operation were documented. Left ventricular diastolic dimension (LVDd), left ventricular systolic dimension (LVDs), and left ventricular ejection fraction (LVEF) were obtained from echocardiographic measurements. Hemodynamic variables by right heart catheterization within 1 month before operation were also evaluated. Among those patients who had been treated with percutaneous cardiopulmonary support, the latest echocardiographic and hemodynamic variables before mechanical support were recruited.
We calculated some indices reported as useful for diagnosing right heart function including right ventricular stroke work index (RVSWI) and pulmonary artery pulsatility index (PAPi), in addition to conventional parameters like pulmonary artery pressure (PAP), pulmonary artery wedge pressure (PAWP), right atrial pressure (RAP), pulmonary vascular resistance (PVR), cardiac output (CO), and cardiac index (CI). PAPi was defined as [(systolic PAP -diastolic PAP)/mean RAP], RVSWI was defined as (mean PAP-mean RAP) × CI × 13.6/heart rate (g/m), and PVR was defined as (mean PAP-mean PAWP)/CO (Wood unit: WU). Endpoints: The endpoint was the incidence of RVAD requirement. RVAD requirement was defined as RVAD implantation at the same time of LVAD implantation and implantation within 2 weeks after LVAD implantation. RVAD implantation was considered when the pump flow of left ventricular support was low despite high central venous pressure (> 15 mmHg), the RV was disproportionally dilated compared to the LV on echocardiography, and the hemodynamics of the patient was unstable in spite of adequate doses of inotropes/pulmonary vasodilators including inhaled nitric oxide after LVAD implantation. As the RVAD device, both Nipro-VAD and centrifugal pumps (Rotaflow or MERA ) were used. Among Bi-VAD patients, when RV function recovered and stable hemodynamics was obtained after the RVAD weaning test, RVAD was removed under multidisciplinary discussion that involved cardiac surgeons, cardiologists, and medical engineers.
Finally, the 2-year survival rate was compared between those who received BiVAD support and LVAD only patients. Among those with BiVAD support, we also compared the survival rates of those who were weaned from RVAD afterward and those with continuous RVAD support. Those who underwent heart transplantation were censored at that time.
Comparison with other predicting scores: We calculated 2 conventional RVAD implantation predicting scoring systems; the right ventricular failure risk score (RVFRS) and the Todai RVAD (TRV) score. RVFRS is the score reported by Matthews, et al using 4 factors as follows; vasopressor use = 4 points, AST (aspartate aminotransferase) !80 IU/L = 2 points, total bilirubin !2.0 mg/dL = 2.5 points, and creatinine !2.3 mg/dL = 3 points. 5) This score is common for assessing RVAD requirement and in cases of RVFRS > 5.5, the long term mortality is reported to be significantly higher. The TRV score is a score which was reported from our institute previously by Shiga, et al using mean RAP/mean PAWP !0.5 = 11 points, BSA (body surface area) < 1.4 m 2 = 7 points, continuous hemodiafiltration: CHDF (+) = 6 points, BNP (B-type natriuretic peptide) > 1200 pg/mL = 8 points, and LVDd < 62 mm = 13 points. 6) A TRV score > 20 was reported to represent a high risk for RVAD implantation. We here evaluated the usefulness of these scores among current subjects. Statistical analysis: All data were analyzed using SPSS Statistics ver. 22 (IBM, Armonk, NY, USA). Statistical tests were two-tailed, and P < 0.05 was defined as significant. Categorical data are presented as frequencies and percentages, and were compared by the chi-square test or Fisher's exact test as appropriate. For continuous variables, the mean and standard deviations are reported and were compared by the unpaired t-test.
Next, univariate logistic analysis was performed for each factor for the RVAD implantation. For consecutive variables, we set the cut-off value by using the ROC curve for RVAD implantation and performed univariate analysis. Finally, multivariate logistic analysis was performed by using factors which showed P < 0.05 in the univariate analysis.
The long-term survival was evaluated by the KaplanMeier method and compared by the pairwise log-rank test.
Results
Baseline clinical characteristics:
Among the 70 patients enrolled, there were 51 males (72.9%) and mean age was 37.2 ± 13.9 years old. Forty-five patients (64.3%) were INTERMACS profile 1 while the other patients were all profile 2. A RVAD was implanted in 14 patients (20%) (3 Nipro-VAD s, 11 centrifugal pumps). The BiVAD group had a significantly higher incidence of fulminant myocarditis (28.6 versus 5.4%, P = 0.026), however, there were no differences with other demographic and laboratory factors (Tables I, II) .
The BiVAD group had significantly smaller LVDd/ LVDs (LVDd: 54.9 ± 11.4 versus 68.1 ± 13.6 mm, P = 0.001, LVDs: 49.5 ± 12.6 versus 61.7 ± 14.1 mm, P = 0.004, respectively). There was no significant difference in LVEF (Table II) .
The BiVAD group presented significantly lower PAWP (20.2 ± 6.7 versus 24.9 ± 7.7 mmHg, P = 0.04), lower CI (1.72 ± 0.27 versus 2.01 ± 0.51 L/minute/m 2 , P = 0.006), higher mean RAP (17.4 ± 4.7 versus 13.0 ± 7.7 mmHg, P = 0.012), lower PAPi (0.99 ± 0.59 versus 2.2 ± 2.2, P = 0.001), higher PVR (4.0 ± 2.0 versus 2.6 ± 1.8 WU, P = 0.014), lower RVSWI (2.97 ± 1.62 versus 5.44 ± 2.73 g/m, P < 0.001), and higher mean RAP/mean RIGHT VENTRICULAR ASSIST DEVICE PREDICTORS PAWP (0.92 ± 0.29 versus 0.51 ± 0.26, P < 0.001) (Table  III) . RVFRS showed no significant differences between the BiVAD group and LVAD only group (P = 0.25), however, the TRV score was significantly higher among the BiVAD group (P < 0.001) (Table III) . Univariate and multivariate analysis for RVAD requirement: From the univariate analysis, fulminant myocarditis as etiology (P = 0.020, odds ratio: OR = 7.1), body height < 160 cm (P = 0.038, OR = 3.7), LVDd < 62 mm (P = 0.008, OR = 5.7), mean RAP/mean PAWP > 0.8 (P < 0.001, OR = 15.0), RVSWI < 5 g/m (P = 0.006, OR = 18.7) , PVR > 4.5 WU (P = 0.002, OR = 8.3), and PAPi < 0.88 (P = 0.004, OR = 7.0) were significant predictors for RVAD requirement. Multivariate analysis showed only PVR > 4.5 WU (P = 0.013, OR = 7.9) and mean RAP/mean PAWP > 0.8 (P < 0.001, OR = 14.4) were significant predictors for RVAD requirement (Table  IV) .
From these two parameters, we constructed a new score which assigned 1 point to PVR > 4.5 and 2 points to mean RAP/mean PAWP > 0.8 based on the OR values.
This new scoring system resulted in a higher AUC compared to the TRV score and RVFRS (New score: 0.853, TRV score: 0.769, RVFRS: 0.594) (Figure 1) .
By using this simple scoring system, the subjects were divided into 4 groups. Although the score 0 group showed only a 4.4% incidence of RVAD requirement (event 2/45), the score 1 group showed 28.6% (event 2/7), score 2 group 41.7% (event 5/12), and score 3 group 83.3% (event 5/6) of RVAD incidence (Figure 2 ). Long-term prognosis: Overall, the RVAD group showed significantly worse survival during the 2-year follow-up period (cumulative survival rate; 28.5% versus 74.4%, P = 0.009).
Nine patients were weaned from RVAD afterward and the mean duration of RVAD support was 15 days (3-44 days), while 5 other patients were persistently with RVAD. Those who were weaned from RVAD afterward had a lower long-term cumulative survival rate compared to the LVAD only patients, however, there was no statistically significant difference (P = 0.13). Those who were persistently with BiVAD had a significantly poor prognosis compared to the other 2 groups (P = 0.003 versus Nitta, ET AL LVAD only group, and P = 0.029 versus weaned from RVAD group) ( Figure 3 ).
Discussion
In this study, we demonstrated the usefulness of combination scoring using PVR and the mean RAP/mean PAWP ratio for the prediction of RVAD requirement among paracorporeal LVAD implanted patients.
Right ventricular failure (RVF) is one of the most serious complications after LVAD implantation and is known to worsen short/long term survival. 7, 8) From some studies, RVF occurs in approximately 15-30% among those who received LVAD implantation. 9) Severe RVF patients who required RVAD are reported to have a high incidence of complications. Compared to LVAD only patients, the incidences of infection were 2 times, bleeding 4 times, and neurological complications 3 times greater among BiVAD patients. 10) In Japan, we are not allowed to use an implantable VAD in INTERMACS profile 1 pa-RIGHT VENTRICULAR ASSIST DEVICE PREDICTORS Table II and III. tients who are not listed for HTx. Consequently, we are obliged to use paracorporeal BiVAD in those who exhibit advanced biventricular failure with cardiogenic shock. Patients with paracorporeal BiVAD have a higher risk of complications and poor QOL and survival. In the present study, the overall cumulative survival was significantly worse among BiVAD patients compared to LVAD only patients (28.5% versus 74.4%, P = 0.009). Although there was no significant difference between those who were weaned from RVAD and LVAD only patients (P = 0.13) as in a previous report, 11) it is obvious that the management of paracorporeal BiVAD is problematic. For these reasons, it is reasonable to stratify the risk of RVAD implantation preoperatively.
Thus far, several risk factors and scoring systems for RVF have been described. Kang, et al reported the usefulness of PAPi for predicting RVAD requirement regardless of the timing of right heart catheterization before implantable LVAD operation. 12) Furthermore, some echocardiographic parameters were identified, such as tricuspid annular dilatation, lower TAPSE (tricuspid annular plane systolic excursion), and longitudinal strain by using speckle strain tracking. 13, 14) However, few studies were designed for only patients with paracorporeal VAD. We examined the predictors of RVAD implantation only among paracorporeal VAD patients, reflecting the situation in that we still use many paracorporeal VADs in Japan.
Mechanisms of RVF after LVAD implantation and role of the present scoring system: The etiology of RVF after LVAD implantation is associated with multiple risk factors; right ventricle (RV) dysfunction owing to the shift of the ventricular septum to the left ventricle (LV) after unloading of LV in addition to the baseline severe RVF before LVAD implantation. This sucking phenomenon is considered to occur when the LV dimension was small. Our group previously reported that a smaller LVDd was a risk factor for late RVF after continuous-flow LVAD implantation. 15) In the present study, a small LVDd was also a risk factor for RVAD requirement, however, it was not significant after multivariate analysis. A hypothesis is that among pulsatile LVAD patients, RV dysfunction is less prominent because of its intermittent unloading of LV, unlike the continuous unloading of implantable LVAD.
Mean RAP/mean PAWP expresses the ratio of filling pressure of RV to LV, and some papers have reported its significance for predicting RVF. Kormos, et al. reported that a mean RAP/mean PAWP ratio of greater than 0.63 was a significant predictor for RVF including RVAD implantation among 484 HeartMate II LVAD implanted patients.
16) It was reported that venous return increases after LVAD implantation owing to the increment of blood transmission to the aorta by LVAD, which causes an increase of RV preload and RVF development. Thus, it is reasonable that the preoperative increase of mean RAP/ mean PAWP is a risk factor which aggravates RV function after LVAD implantation.
PVR is a marker of the remodeling of pulmonary artery as well as a direct index of RV afterload. Previously, we reported that a lower PVR would be an essential factor for maintaining the hemodynamics of those with sustained ventricular tachyarrhythmia after continuous-flow LVAD implantation.
17) It was also reported that PVR is associated with the risk of RVF. Drakos, et al. reported a PVR "4.3 WU had more RVF risk (P = 0.012, OR = 4.1) compared to those with PVR !1.7 WU. 18) Among HF patients, vasospasm and endothelium damage from hypoxia gradually leads to remodeling of the pulmonary artery. Furthermore, severe circulatory failure patients like INTERMACS profile 1 are reported to have high levels of inflammatory cytokines such as interleukin-6, monocyte chemoattractant protein-1, tumor necrosis factor-α, and vascular endothelial growth factor. 19) These are all risk factors for pulmonary vascular remodeling resulting in elevated PVR.
Comparison with other scoring systems:
In the present study, RVFRS was not useful for predicting RVAD implantation. RVFRS included several kinds of intracorporeal VAD such as HeartMate 1000 IP , HeartMate VE , HeartMate XVE , HeartMate II , and Novacor , and half of the subjects had an ischemic etiology. These differences in the population would be the reason for its low usefulness for predicting RVAD requirement in the present subjects. Furthermore, although RVFRS defines AST > 80 IU/L as a significant factor, the average AST in our subjects was 168.1 IU/L and most of our patients matched this criterion. RVFRS included many BTT patients, so the population might be somewhat better compared to our subjects.
The TRV score was comparatively useful, most likely because it was a score which was reported from our institute previously. However, the TRV score was constructed from the cohort that included both pulsatile and continuous-flow VADs. As mentioned above, the effect on RV function and hemodynamics must be different between pulsatile VAD and continuous-flow VAD, therefore, it would be inappropriate to perform an analysis among a cohort including both types of VADs. Actually, the patients who required RVAD in our institute were all those with paracoporeal pulsatile VAD, probably due to the relatively better conditions of those who received an implantable LVAD (= all for BTT and relatively good RV function). Furthermore, the TRV score was calculated based on only univariate analysis, which means there is a possibility of biases by confounding factors. The present scoring system is considered to be useful from the viewpoint that we examined only paracorporeal pulsatile VAD and performed multivariate analysis using detailed hemodynamic parameters including PAPi. For further assessment of this scoring method, it is necessary to perform prospective investigation using another validation cohort. Future perspectives: By stratifying RVAD implantation risk preoperatively, we should be able to avoid unplanned RVAD implantation. Several papers have suggested that unplanned RVAD implantation further worsens the prognosis more than planned RVAD implantation. 20) Our novel prediction score may be useful in this respect.
Furthermore, our study suggested the possibility of preventing RVAD by lowering PVR and mean RAP/mean PAWP preoperatively. We would be able to lower PVR and mean RAP/mean PAWP by using an aggressive pulmonary vasodilator and controlling intravascular volume strictly before the LVAD operation. There are no studies that have examined whether such preoperative interventions reduce the need for RVAD. In the future, larger prospective studies should be conducted. Study Limitations: 1) Since this study was conducted retrospectively in a small number of patients at a single institution, we have to admit that potential selection bias exists. 2) Because this study included 2 periods, one in which implantable VADs were approved and one in which they were not, there may be differences in the clinical situations of the subjects who received paracorporeal VAD implantation. The present study included only profile 1 and profile 2 patients and the distribution of profile 1 was not significantly different between those who received paracorporeal VAD implantation before and after implantable VAD approval (P = 0.43). However, the indication for paracorporeal pulsatile VADs sometimes depends on multiple factors such as caregiver problems, so the situation of pulsatile VAD implantation should be explored in detail in the future in order to resolve selection bias. 3) In the present study, we were unable to assess some important echocardiographic parameters, such as tricuspid regurgitation and TAPSE because there were many patients who lacked these parameters. Although these parameters were difficult to measure accurately in critically ill patients like INTERMACS profile 1 patients who required RIGHT VENTRICULAR ASSIST DEVICE PREDICTORS Figure 3 . Two-year cumulative survivals of the BiVAD group and LVAD only group (A). The survival rates of those who were weaned from RVAD afterward and those who were persistently with RVAD support are also presented (B).
paracorporeal VAD implantation immediately, we need to study these non-invasive and useful markers in the future. 4) We need to determine whether our novel score is useful for implantable LVAD cohorts in Japan.
Conclusions
The combination score using PVR > 4.5 WU and mean RAP/mean PAWP > 0.8 is a useful predictor for RVAD implantation among those who require paracorporeal LVAD. This easy score to obtain would be helpful for stratifying the risk of RVAD requirement.
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